COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Therapy and Peer Support for Patients Taking Medication for Opioid Use Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04257214
Recruitment Status : Recruiting
First Posted : February 5, 2020
Last Update Posted : July 16, 2020
Boston University
Patient-Centered Outcomes Research Institute
Public Health Management Corporation
University of Pennsylvania
Information provided by (Responsible Party):
Philadelphia College of Osteopathic Medicine

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : April 30, 2023
Estimated Study Completion Date : April 30, 2023
Substance Abuse and Mental Health Services Administration. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP) Series, No. 40 (SMA 04-3939). Rockville, MD: U.S. Department of Health and Human Services; 2004.
Department of Health and Human Services. Medication assisted treatment for opioid use disorder (42 CFR Part 8, RIN 0930-AA22). Rockville, MD: Substance Abuse and Mental Health Services Administration.
Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database of Systematic Reviews; 2011. Retrieved from Accessed September 6, 2018.